Skip to main content Accessibility help

Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2

  • L Fegn (a1) (a2) and Z Wang (a1)



Skin cancer is the most common cancer, and often occurs in the head and neck region. This study aimed to investigate whether a combination of inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase, applied via a microemulsion delivery system, would be effective in topically inhibiting skin carcinogenesis.

Study design:

Randomised animal study.


Twenty-four nude mice were intradermally inoculated with carcinoma cells and then divided into three groups (eight animals each): group one received no treatment; group two received celecoxib alone; and group three received a combination of zileuton and celecoxib. Tumour incidence and growth were measured for 14 days.


Both treatments significantly delayed the onset and development of tumours. However, the combined treatment had the best response (p < 0.01).


The results clearly showed that topical treatment with either celecoxib alone or celecoxib plus zileuton significantly inhibited skin carcinogenesis, and that a combination of both agents had the best results.


Corresponding author

Address for correspondence: Dr Zhi Wang, 820 Harrison Ave 4014, Boston, MA 02118, USA. Fax: +1 617 414 1591 E-mail:


Hide All

Presented as a poster at the 14th European Cancer Conference, 23–27 September 2007, Barcelona, Spain.



Hide All
1 Jemal, A, Siegel, R, Ward, E, Murray, T, Xu, J, Thun, MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:4366
2 Tsao, AS, Kim, ES, Hong, WK. Chemoprevention of cancer. CA Cancer J Clin 2004;54:150–80
3 Wang, W, Polavaram, R, Shapshay, SM. Topical inhibition of oral carcinoma cell with polymer delivered celecoxib. Cancer Lett 2003;198:53–8
4 Wilgus, TA, Koki, AT, Zweifel, BS, Rubal, PA, Oberyszyn, TM. Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. Mol Carcinog 2003;38:33–9
5 Wilgus, TA, Breza, TS Jr, Tober, KL, Oberyszyn, TM. Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors. J Invest Dermatol 2004;122:1488–94
6 Steele, VE, Holmes, CA, Hawk, ET, Kopelovich, L, Lubet, RA, Crowell, JA et al. Lipoxygenase inhibitors as potential cancer. Chemopreventives. Cancer Epidemiol Biomarkers Prev 1999;8:467–83
7 Ye, YN, Wu, WK, Shin, VY, Bruce, IC, Wong, BC, Cho, CH. Dual inhibition of 5-LOX and COX-2 suppress colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005;26:827–34
8 Li, N, Sood, S, Wang, S, Fang, M, Wang, P, Sunet, Z et al. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 2005;11:2089–96
9 Yan, Y, Wang, B, Zuo, YG, Qu, T. Inhibitory effects of mizolastine on ultraviolet B-induced leukotriene B4 production and 5-lipoxygenase expression in normal human dermal fibroblasts in vitro. Photochem Photobiol 2006;82:665–9
10 Subramanian, N, Ghosal, SK, Moulik, SP. Topical delivery of celecoxib using microemulsion. Acta Pol Pharm 2004;61:335–41
11 Shureiqi, I, Lippman, M. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001;61:6307–12
12 Ara, G, Teicher, BA. Cyclooxygenase and lipoxygenase inhibitors in cancer therapy. Prostaglandins Leukot Essent Fatty Acids 1996;54:316
13 Wilgus, TA, Koki, AT, Zweifel, BS, Kusewitt, DF, Rubal, PA, Oberyszyn, TM. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog 2003;38:4958
14 Buchanan, FG, Wang, D, Bargiacchi, F, DuBois, RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003;278:35451–7
15 Pentland, AP, Schoggins, JW, Scott, GA, Khan, KN, Han, R. Reduction of UV induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999;20:1939–44
16 Hebert, MJ, Takano, T, Holthofer, H, Brady, HR. Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase-derived eicosanoids. J Immunol 1996;157:3105–15
17 Read, NG, Astbury, PJ, Evans, GO, Goodwin, DA, Rowlands, A. Nephrotic syndrome associated with N-hydroxyureas, inhibitors of 5-lipoxygenase. Arch Toxicol 1995;69:480–90
18 Sun, Z, Sood, S, Li, Z, Ramji, D, Yang, P, Newman, RA et al. Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors. Carcinogenesis 2006;27:1902–8
19 Yener, G, Gonullu, U, Uner, M, Degim, T, Araman, A. Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of celecoxib through human skin. Pharmazie 2003;58:330–3
20 Natesan, S, Saroj, SG, Asis, A, Satya, PM. Formulation and physicochemical characterization of microemulsion system using isopropyl myristate, medium-chain glyceride, polysorbate 80 and water. Chem Pharm Bull 2005;53:1530–5



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed